Nachweis zirkulierender Tumorzellen aus dem Blut von Brustkrebspatientinnen anhand der Genexpression von Cytokeratin 8, 18 und 19

Zebisch, M; Andergassen, U; Kölbl, AC; Heublein, Sabine; Jäger, B; Neugebauer, Jörg; Rack, B; Friese, Klaus; Jeschke, Udo

doi:10.1055/s-0032-1318586

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One such method is utilized by the CellSearch System (Veridex, LLC, Warren, NJ, USA), a device approved by the US Food and Drug Administration (FDA) in 2004 for the detection of CTCs in the peripheral blood of patients with MBC. Another approach is to perform RT-PCR measurement of cytokeratin (CK) mRNA expression levels (CK19, CK20) which are used as surrogate for the presence of CTCs in the peripheral blood and which have been shown to correlate with disease outcome and the results from CellSearch [23,24]. The great hope regarding the CTCsʼ clinical relevance is that by characterizing their individual phenotype and/or genotype clinicians will be able to target the Achilles heel of these CTCs which are finally responsible for metastasis in order to improve prognosis and prediction.…”

Section: The Concept Of Circulating Tumor Cellsmentioning

confidence: 99%

Prognostic Relevance of Circulating Tumor Cells in Molecular Subtypes of Breast Cancer

Banys-Paluchowski

Schneck

Blassl

et al. 2015

Geburtshilfe Frauenheilkd

View full text Add to dashboard Cite

Circulating tumor cells (CTCs) can be detected in the peripheral blood of breast cancer patients with early and metastatic disease. Recent data suggest that immune pathologic characteristics between the primary tumor, metastatic colonies and CTCs are discordant and that CTCs possess an independent phenotype that is associated with prognosis and treatment efficacy. Large scale gene expression analysis has provided the possibility to stratify breast cancer according to the gene expression fingerprint of primary tumor tissue into five intrinsic molecular subtypes which can be associated with different clinical outcome. As a consequence of the different prognostic power of primary tumors' characteristics and CTCs several groups have started to investigate if CTCs might be disseminated differentially within these breast cancer subtypes. They determined the CTC number in immunohistochemical subtypes to validate if CTCs may provide differential and more specific prognostic information within each subtype. This review provides an overview of the outcome of some recently published data gathered from early and metastatic breast cancer.

show abstract

Section: The Concept Of Circulating Tumor Cellsmentioning

confidence: 99%